ABC Proteins Involved in Protozoan Parasite Resistance

ABC Transporters and Multidrug Resistance

Volumn , Issue , 2009, Pages 195-238

  Pradines, Bruno ^a,b  

^a SERVICE DE SANTÉ DES ARMÉES   (France)

^b CNRS   (France)

Author keywords

ABC proteins in protozoan parasite resistance; ABC transporters and MDR in leishmania spp.; ABC transporters and MDR in plasmodium spp.

Indexed keywords

EID: 77953827737     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470495131.ch7     Document Type: Chapter

References (288)

1. Sparreboom A, Danesi R, Ando Y, Chan J, and Figg WD. 2003. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Update 6: 71-84.
2. Ambudkar SV, Rosen BP, and Gottesman MM. 2000. Workshop on ABC transporters and human diseases. Drug Resist Update 3: 51-54.
3. Lage H. 2003. ABC-transporters: Implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22: 188-199.
4. Schuetzer-Muehlbauer M, Willinger B, Egner R, Ecker G, and Kuchler K. 2003. Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. Int J Antimicrob Agents 22: 291-300.
5. Rubio JP and Cowman AF. 1996. The ATP-binding cassette (ABC) gene family of Plasmodium falciparum. Parasitol Today 12: 135-140.
6. Perez-Martin O, Lastre Gonzalez M, Urban M, and Shwalbach J. 1991. In vivo resistance to strains of Trypanosoma rhodesiense, Mozambique, 1985. Rev Cubana Med Trop 43: 189-193.
7. Legros D, Fournier C, Gastellu Etchegorry M, Maiso F, and Szumilin E. 1999. Therapeutic failure of melarsoprol among patients treated for stage T. b. gam-biense human African trypanosomiasis in Uganda. Bull Soc Pathol Exot 92: 171-172.
8. Matovu E, Enyaru JC, Legros D, Schmid C, Seebeck T, and Kaminsky R. 2001. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop Med Int Health 6: 407-411.
9. Stanghellini A and Josenando T. 2001. The situation of sleeping sickness in Angola: A calamity. Trop Med Int Health 6: 330-334.
10. Welburn SC and Odiit M. 2002. Recent developments in human African trypanosomiasis. Curr Opin Infect Dis 15: 477-484.
11. Legros D, Ollivier G, Gastellu Etchegorry M, Paquet C, Burri C, Jannin J et al. 2002. Treatment of human African trypanosomiasis-Present situation and needs for research and development. Lancet Infect Dis 2: 437-440.
12. Morel CM. 2000. Reaching maturity-25 years of the TDR. Parasitol Today 16: 522-528.
13. World Health Organization. 2005. TDR Seventeenth Programme Report, Progress 2003-2004.
14. Urbina JA. 2002. Chemotherapy of Chagas disease. Curr Pharm Des 8: 287-295.
15. Urbina JA and Docampo R. 2003. Specific chemotherapy of Chagas disease: Controversies and advances. Trends Parasitol 19: 495-501.
16. Andrade SG, Rassi A, Magalhaes JB, Ferriolli Filho F, and Luquetti AO. 1992. Specific chemotherapy of Chagas disease: A comparison between the response in patients and experimental animals inoculated with the same strains. Trans R Trop Med Hyg 86: 624-626.
17. Cançado JR. 1999. Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz 94: 331-335.
18. Murta SMF, Gazzinelli RT, Brener Z, and Romanha AJ. 1998. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol 93: 203-214.
19. Veloso VM, Carneiro CM, Toledo MJO, Lana M, Chiari E, Tafuri WL et al. 2001. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz 96: 1005-1011.
20. De Ornelas Toledo MJ, Bahia MT, Carneiro CM, Martins-Filho OA, Tibayrenc M, Barnabé C et al. 2003. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes. Antimicrob Agents Chemother 47: 223-230.
21. Camandaroba ELP, Reis EAG, Gonçalves MS, Reis MG, and Andrade SG. 2003. Trypanosoma cruzi: Susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop 36: 201-209.
22. Dallagiovanna B, Castanys S, and Gamarro F. 1994. Trypanosoma cruzi: Sequence of the ATP-binding site of a P-glycoprotein gene. Exp Parasitol 79: 63-67.
23. Torres C, Barreiro L, Dallagiovanna B, Gamarro F, and Castanys S. 1999. Characterization of a new ATP-binding cassette transporter in Trypanosoma cruzi associated to a L1Tc retrotransposon. Biochim Biophys Acta 1489: 428-432.
24. Murta SMF, dos Santos WG, Anacleto C, Nirdé P, Moreira ESA, and Romanha AJ. 2001. Drug resistance in Trypanosoma cruzi is not associated with amplification or overexpression of P-glycoprotein (PGP) genes. Mol Biochem Parasitol 117: 223-228.
25. Dallagiovanna B, Gamarro F, and Castanys S. 1996. Molecular characterization of a P-glycoprotein-related tcpgp2 gene in Trypanosoma cruzi. Mol Biochem Parasitol 75: 145-157.
26. Torres C, Perez-Victoria FJ, Parodi-Talice A, Castanys S, and Gamarro F. 2004. Characterization of an ABCA-like transporter involved in trafficking in the protozoan parasite Trypanosoma cruzi. Mol Microbiol 54: 632-646.
27. Maser P and Kaminsky R. 1998. Identification of three ABC transporter genes in Trypanosoma brucei spp. Parasitol Res 84: 106-111.
28. Shahi SK, Krauth-Siegel RL, and Clayton CE. 2002. Overexpression of the putative thiol conjugate transporter TbMRP causes melarsoprol resistance in Trypanosoma brucei. Mol Microbiol 43: 1129-1138.
29. Fairlamb AH, Carter NS, Cunningham M, and Smith K. 1992. Characterization of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol Biochem Parasitol 53: 213-222.
30. Carter NS, Berger BJ, and Fairlamb AH. 1995. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and-resistant Trypanosoma brucei brucei. J Biol Chem 270: 28153-28157.
31. de Koning HP and Jarvis SM. 2001. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter. Acta Trop 80: 245-250.
32. de Koning HP. 2001. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: Implications for cross-resistance with arsenicals. Mol Pharmacol 59: 586-592.
33. Barrett MP, Zhang ZQ, Denise H, Giroud C, and Baltz T. 1995. A diamine-resistant Trypanosoma equiperdum clone containing purine transporter with reduced substrate affinity. Mol Biochem Parasitol 73: 223-229.
34. Matovu E, Stewart ML, Geiser F, Brun R, Mäser P, Wallace LJM et al. 2003. Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukariot Cell 2: 1003-1008.
35. de Koning HP, Anderson LF, Stewart M, Burchmore RJS, Wallace LJM, and Barrett MP. 2004. The trypanocide diminazene acturate is accumulated predominantly through the TbAT1 purine transporter: Additional insights on diamidine resistance in African trypanosomes. Antimicrob Agents Chemother 48: 1515-1519.
36. Ouellette M, Fase-Fowler F, and Borst P. 1990. The amplified H circle of methotrexate-resistant Leishmania tarentolae contains a novel P-glycoprotein gene. EMBO J 9: 1027-1033.
37. Martin F, Maranon C, Olivares M, Alonso C, and Lopez J. 1995. Characterization of a non-long terminal repeat retrotransposon cDNA (L1Tc) from Trypanosoma cruzi. Homology of the first ORF with the Ape family of DNA repair enzymes. J Mol Biol 247: 49-59.
38. Lara FA, Sant'Anna C, Lemos D, Laranja GAT, Coelho MGP, Reis Salles I et al. 2007. Heme requirement and intracellular trafficking in Trypanosoma cruzi epi-mastigotes. Biochem Biophys Res Com 355: 16-22.
39. Neal RA, van Bueren J, McCoy NG, and Iwobi M. 1989. Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. Trans R Soc Trop Med Hyg 83: 197-198.
40. Kaminsky R and Zweygarth E. 1991. The effect of verapamil alone and in combination with trypanocides on multidrug-r esistant Trypanosoma brucei brucei. Acta Trop 49: 215-225.
41. Anene BM, Ross CA, Anika SM, and Chukwu CC. 1996. Trypanocidal resistance in Trypanosoma evansi in vitro: Effects of verapamil, cyproheptadine, desipramine and chlorpromazine alone and in combination with trypanocides. Vet Parasitol 62: 43-50.
42. Rivarola HW and Paglini-Oliva PA. 2002. Trypanosoma cruzi trypanothione reductase inhibitors: Phenothiazines and related compounds modify experimental disease evolution. Curr Drug Targets Cardiovasc Haematol Disord 2: 43-52.
43. Rosypal AC, Troy GC, Zajac AM, Duncan RB, Waki K, Chang KP et al. 2003. Emergence of zoonotic canine leishmaniasis in the United States: Isolation and immunohistochemical detection of Leishmania infantum from foxhounds from Virginia. J Eukaryot Microbiol 50: 691-693.
44. Ollivier L, Michel R, Spiegel A, and Boutin JP. 2004. Measures of impact on epidemiology. Med Trop 64: 71-74.
45. Berger F, Romary P, Brachet D, Rapp C, Imbert P, Carrabé E et al. 2006. Outbreak of cutaneous leishmaniasis in military population coming back from French Guiana. Rev Epidemiol Sante Publique 54: 213-221.
46. Jackson JE, Tally JD, Ellis WY, Mebrahtu YB, Lawyer PG, Were JB et al. 1990. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania spp. From patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg 43: 464-480.
47. Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, Michel G et al. 1997. In vitro and in vivo resistance of Leishmania infantum to meglumine anti-moniate: A study of 37 strains collected from patients with visceral Leishmaniasis. Antimicrob Agents Chemother 41: 827-830.
48. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A et al. 2000. Failure of pentavalent antimony in visceral Leishmaniasis in India: Report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1107.
49. Ellenberger TE and Beverley SM. 1989. Multiple drug resistance and conservative amplification of the H region in Leishmania major. J Biol Chem 264: 15094-15103.
50. Detke S, Katakura K, and Chang KP. 1989. DNA amplification in arsenite-resistant Leishmania. Exp Cell Res 180: 161-170.
51. Callahan HL and Beverley SM. 1991. Heavy metal resistance: A new role for P-glycoproteins in Leishmania. J Biol Chem 266: 18427-18430.
52. Legare D, Hettema E, and Ouellette M. 1994. The P-glycoprotein-related gene family in Leishmania. Mol Biochem Parasitol 68: 81-91.
53. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654.
54. Ouellette M, Drummelsmith J, and Papadopoulou B. 2004. Leishmaniasis: Drugs in the clinic, resistance and new developments. Drug Resist Update 7: 257-266.
55. Gamarro F, Chiquero MJ, Amador MV, Lagare D, and Ouellette M. 1994. P-glycoprotein overexpression in methotrexate-resistant Leishmania tropica. Biochem Pharmacol 47: 1939-1947.
56. Borst P and Ouellette M. 1995. New mechanisms of drug resistance in parasitic protozoa. Annu Rev Microbiol 49: 427-460.
57. Papdopoulou B, Kunding C, Singh A, and Ouellette M. 1998. Drug resistance in Leishmania: Similarities and differences to other organisms. Drug Resist Updat 1: 266-278.
58. Chow LMC and Volkman K. 1998. Plasmodium and Leishmania: The role of mdr genes in mediating drug resistance. Exp Parasitol 90: 135-141.
59. Ouellette M, Legare D, and Papadopoulou B. 2001. Multidrug resistance and ABC transporters in parasitic protozoan. J Mol Microbiol Biotechnol 3: 201-206.
60. Légaré D, Richard D, Mukhopadhyay R, Stierhof YD, Rosen BP, Haimeur A et al. 2001. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. JBiol Chem 276: 26301-26307.
61. Papadopoulou B, Roy G, Dey S, Rosen BP, and Ouellette M. 1994. Contribution of the Leishmania P-glycoprotein-related gene LtpgpA to oxyanion resistance. J Biol Chem 269: 11980-11986.
62. Haimeur A, Brochu C, Genest PA, Papadopoulou B, and Ouellette M. 2000. Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae. Mol Biochem Parasitol 108: 131-135.
63. Grondin K, Haimeur A, Mukhopadhyay R, Rosen BP, and Ouellette M. 1997. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J 16: 3057-3065.
64. Mukhopadhyay R, Dey S, Xu N, Gage D, Lighbody J, Ouellette M et al. 1996. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci USA 93: 10383-10387.
65. Dey S, Papadopoulou B, Haimeur A, Roy G, Grondin K, Dou D et al. 1994. High level arsenite resistance in Leishmania tarentolae is mediated by an active extrusion system. Mol Biochem Parasitol 67: 49-57.
66. Dey S, Ouellette M, Lightbody J, Papadopoulou B, and Rosen BP. 1996. An ATP-dependent As (III)-gluththione transport system in membrane vesicles of Leishmania tarentolae. Proc Natl Acad Sci USA 93: 2192-2197.
67. Légaré D, Papadopoulou B, Roy G, Mukhopadhyay R, Haimeur A, Dey S et al. 1997. Efflux system and increased trypanothine levels in arsenite-resistant Leishmania. Exp Parasitol 87: 275-282.
68. Wang HF and Lee TC. 1993. Glutathione S-transferase pi facilitates the excretion of arsenic from arsenic-resistant Chinese hamster ovary cells. Biochem Biophys Res Commun 192: 1093-1099.
69. Hendrickson N, Sifri CD, Henderson DM, Allen T, Wirth DF, and Ullman B. 1993. Molecular characterization of the Ldmdr1 multidrug resistance gene from Leishmania donovani. Mol Biochem Parasitol 60: 53-64.
70. Henderson DM, Sifri CD, Rodgers M, Wirth DF, Hensrickson N, and Ullman B. 1992. Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene. Mol Cell Biol 12: 2855-2865.
71. Chow LM, Wong AK, Ullman B, and Wirth DF. 1993. Cloning and functional analysis of an extrachromosomally amplified multidrug resistance-like gene in Leishmania enriettii. Mol Biochem Parasitol 60: 195-208.
72. Katakura K, Iwanami M, Ohtomo H, Fujise H, and Hashiguchi Y. 1999. Structural and functional analysis of the LaMDR1 multidrug resistance gene in Leishmania amazonensis. Biochem Biophys Res Commun 255: 289-294.
73. Gueiros-Filho FJ, Viola JPB, Gomes FCA, Farina M, Lins U, Bertho AL et al. 1995. Leishmania amazonensis: Multidrug resistance in vinblastine-resistant promasti-gotes is associated with Rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdr1 gene. Exp Parasitol 81: 480-490.
74. Chiquero MJ, Perez-Victoria JM, O'Valle F, Gonzales-Ros JM, del Moral RG, Ferragut JA et al. 1998. Altered drug membrane permeability in a multidrug-resistant Leishmania tropica line. Biochem Pharmacol 55: 131-139.
75. Dey S, Ouellette M, and Rosen BP. 1999. ATP-binding cassette transporters: From multidrug resistance to genetic disease. Drug Resist Updat 2: 130-133.
76. Dodge MA, Waller RF, Chow LM, Zaman MM, Cotton LM, McConville MJ et al. 2004. Localization and activity of multidrug resistance protein 1 in the secretory pathway of Leishmania parasites. Mol Microbiol 51: 1563-1575.
77. Klokouzas A, Shahi S, Hladky SB, Barrand MA, and van Veen HK. 2003. ABC transporters and drug resistance in parasitic protozoa. Int J Antimicrob Agents 22: 301-317.
78. Mullin AK, Foth BJ, Ilgoutz SC, Callaghan JM, Zawadzki JL, McFadden GI et al. 2001. Regulated degradation of an endoplasmatc reticulum membrane protein in a tubular lysosome in Leishmania mexicana. Mol Biol Cell 12: 2364-2377.
79. McConville MJ, Mullin KA, Ilgoutz SC, and Teasdale RD. 2002. Secretory pathway of trypanosomatid parasites. Microbiol Mol Biol Rev 66: 122-154.
80. Wrong ILK and Chow LMC. 2006. The role of Leishmania enriettii multidrug resistance protein 1 (LeMDR1) in mediating drug resistance is iron-dependent. Mol Biochem Parasitol 150: 278-287.
81. Katakura K, Fujise H, Takeda K, Kanedo O, Torii M, Suzuki M et al. 2004. Overexpression of LaMDR2, a novel multidrug resistance ATP-binding cassette transporter, causes 5-fluorouracil resistance in Leishmania amazonensis. FEBS Lett 561: 207-212.
82. Parodi-Talice A, Araujo JM, Perez-Victoria M, Gamarro F, and Castanys S. 2003. The overexpression of a new ABC transporter in Leishmania is related to phospholipid trafficking and reduced infectivity. Biochim Biophys Acta 1612: 195-207.
83. Hamon Y, Broccardo C, Chambenoit O, Luciani MF, Toti F, Chaslin S et al. 2000. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat Cell Biol 2: 399-406.
84. Stein WD. 2002. Reversers of the multidrug resistance transporter P-glycoprotein. Curr Opin Invest Drugs 3: 812-817.
85. Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972.
86. Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y. 1983. Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 43: 2267-2272.
87. Twentyman PR, Fox NE, and Bleehen NM. 1986. Drug resistance in human lung cancer cell lines: Cross-resistance studies and effects of the calcium transport blocker, verapamil. J Radiat Oncol Biol Phys 12: 1355-1358.
88. Banerjee SK, Bhatt K, Rana S, Misra P, and Chakraborti PK. 1996. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Biochem Biophys Res Commun 226: 362-368.
89. Choudhuri BS, Bahkta S, Barik R, Basu J, Kundu M, and Chakrabarti P. 2002. Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochem J 367: 279-285.
90. Jonas BM, Murray BE, and Weinstock GM. 2001. Characterization of emeA, a NorA homolog and multidrug resistance efflux pump, in Enterococcus faecalis. Antimicrob Agents Chemother 45: 3574-3579.
91. Beugnet F, Gauthey M, and Kerboeuf D. 1997. Partial in vitro reversal of benz-imidazole resistance by the free-living stages of Haemonchus contortus with verapamil. Vet Rec 141: 575-576.
92. Kerboeuf D, Chambrier P, Le Vern Y, and Aycardi J. 1999. Flow cytometry analysis of drug transport mechanisms in Haemonchus contortus susceptible or resistant to antihelminthics. Parasitol Res 85: 118-123.
93. Kerboeuf D, Blackhall W, Kaminsky R, and von Samson-Himmelstjerna G. 2003. P-glycoprotein in helminths: Function and perspectives for antihelminthic treatment and reversal of resistance. Int J Antimicrob Agents 22: 332-346.
94. Ayala P, Samuelson J, Wirth D, and Orozco E. 1990. Entamoeba histolytica: Physiology of multidrug resistance. Exp Parasitol 71: 169-175.
95. Banuelos C, Orozco E, Gomez C, Gonzales A, Medel O, Mendoza L et al. 2002. Cellular location and function of the P-glycoprotein (EhPgp) in Entamoeba histolytica multidrug-resistant trophozoites. Microb Drug Resist 8: 291-300.
96. Orozco E, Lopez C, Gomez C, Perez DG, Marchat L, Banuelos C et al. 2002. Multidrug resistance in the protozoan parasite Entamoeba histolytica. Parasitol Int 51: 353-359.
97. Martin SK, Oduola AM, and Milhous WK. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235: 899-901.
98. Ryall JC. 1987. Reversal of chloroquine resistance in falciparum malaria. Parasitol Today 3: 256.
99. Essodaïgui M, Frézard F, Moreira ESA, Dagger F, and Garnier-Suillerot A. 1999. Energy-dependent effux from Leishmania promastigotes of substrates of the mammalian multidrug resistance pumps. Mol Biochem Parasitol 100: 73-84.
100. Kaur J and Dey CS. 2000. Putative P-glycoprotein expression in arsenite-resistant Leishmania donovani down-regulated by verapamil. Biochem Biophys Res Commun 271: 615-619.
101. Loe DW, Deeley RG, and Cole SPC. 2000. Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 293: 530-538.
102. Loe DW, Oleschuk CJ, Deeley RG, and Cole SPC. 2000. Structure-activity studies of verapamil analogs that modulate transport of Leukotriene C4 and reduced gluththione by multidrug resistance protein MRP1. Biochem Biophys Res Commun 275: 795-803.
103. Perez-Victoria JM, Chiquero MJ, Conseil G, Dayan G, di Pietro A, Barron D et al. 1999. Correlation between the affinity of flavonoids binding to the cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin. Biochemistry 38: 1736-1743.
104. Di Pietro A, Conseil G, Perez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D et al. 2002. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59: 307-322.
105. Kennedy ML, Cortés-Selva F, Perez-Victoria JM, Jimenez I A, Gonzales AG, Munoz OM et al. 2001. Chemosensitization of a multidrug-resistant Leishmania tropica line by new sesquiterpenes from Maytenus magellanica and Maytenus chubutensis. J Med Chem 44: 4668-4676.
106. Wrong ILK, Chan KF, Burkett BA, Zhao Y, Chai Y, Sun H et al. 2007. Flavonoid dimmers as bivalent modulators for pentamidine and sodium stiboglucanate resistance in Leishmania. Antimicrob Agent Chemother 51: 930-940.
107. Shapiro AB and Ling V. 1997. Effect of Quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 53: 587-596.
108. Maitrejean M, Comte G, Barron D, El Kirat K, Conseil G, and di Pietro A. 2000. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg Med Chem Lett 10: 157-160.
109. Critchfield JW, Welsh CJ, Phang JM, and Yeh GC. 1994. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48: 1437-1445.
110. Shapiro AB and Ling V. 1997. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250: 130-137.
111. Ferté J, Kühnel JM, Chapuis G, Rolland Y, Lewin G, and Schwaller MA. 1999. Flavonoid-related modulators of multidrug resistance: Synthesis, pharmacological activity, and structure-activity relationships. J Med Chem 42: 478-489.
112. Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, and Barron D. 1998. Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95: 9831-9836.
113. Perez-Victoria JM, Perez-Victoria FJ, Parodi-Talice A, Jimenez IA, Ravelo AG, Castanys S et al. 2001. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother 45: 2468-2474.
114. Kioka N, Hosokawa N, Komano T, Hirayoshi K, Nagata K, and Ueda K. 1992. Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite. FEBS Lett 301: 307-309.
115. Perez-Victoria JM, Tincusi BM, Jimanez IA, Bazzocchi IL, Gupta MP, Castanys S et al. 1999. New natural sesquiterpenes as modulators of daunomycin resistance in a multidrug-resistant Leishmania tropica line. J Med Chem 42: 4388-4393.
116. Cortes-Selva F, Campillo M, Reyes CP, Jimenez IA, Castanys S, Bazzocchi IL et al. 2004. SAR studies of dihydro-beta-agarofuran sesquiterpenes as inhibitors of the multidrug-resistance phenotype in a Leishmania tropica line overexpressing a P-glycoprotein-like transporter. J Med Chem 47: 576-587.
117. Perez-Victoria JM, Cortes-Selva F, Parodi-Talice A, Bavchvarov BI, Perez-Victoria FJ, Munoz-Martinez F et al. 2006. Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to miltefosine by inhibiting drug efflux. Antimicrob Agent Chemother 50: 3102-3110.
118. Cortes-Selva F, Jimenez IA, Munoz-Martinez F, Campillo M, Bazzocchi IL, Pardo L et al. 2005. Dihydro-beta-agarofuran sesquiterpenes: A new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite Leishmania. Curr Pharm Des 11: 3125-3139.
119. Cortes-Selva F, Munoz-Martinez F, Ilias A, Jimenez IA, Varadi A, Gamarro F et al. 2005. Functional expression of a multidrug P-glycoprotein transporter of Leishmania. Biochim Biophys Res Commun 329: 502-507.
120. Callaghan R, van Gorkom LC, and Epand RM. 1992. A comparison of membrane properties and composition between cell lines selected and transfected for multidrug resistance. Br J Cancer 66: 781-786.
121. Storme GA, Berdel WE, van Blitterswijk WJ, Bruyneel EA, de Bruynen GK, and Marell MM. 1985. Anti-invasive effect of racemic1-O-octadecyl-2-O-methylglycero-phosphocholine on MO4 mouse fibrosarcoma cells in vitro. Cancer Res 45: 351-357.
122. Ford JM, Prozialeck WC, and Hait WN. 1989. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35: 105-115.
123. Ramu A and Ramu N. 1992. Reversal of multidrug resistance by phenothia-zines and structurally related compounds. Cancer Chemother Pharmacol 30: 165-173.
124. Molnar J, Hever A, Falka I, Ocsovski I, and Aszalos A. 1997. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells. Anticancer Res 17: 481-486.
125. Kaatz GW, Moudgal VV, Seo SM, and Kristiansen JE. 2003. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother 47: 719-726.
126. Pearce HL, Safa AR, Bac, NJ, Winter MA, Cirtain MC, and Beck WT. 1989. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 86: 5128-5132.
127. Pearson RD, Manian AA, Harcus JL, Hall D, and Hewlett EL. 1982. Lethal effect of phenothiazine neuroleptics on the pathogenic protozoan Leishmania donovani. Science 217: 369-371.
128. Pearson RD, Manian A A, Hall D, Harcus JL, and Hewlett EL. 1984. Antileishmanial activity of chlorpromazine. Antimicrob Agents Chemother 25: 571-574.
129. Werbovetz KA, Lehnert EK, MacDonald TL, and Pearson RD. 1992. Cytotoxicity of acridine compounds for Leishmania promastigotes in vitro. Antimicrob Agents Chemother 36: 495-497.
130. el-On J, Rubinstein N, Kernbaum S, and Schnur LF. 1986. In vitro and in vivo anti-leishmanial activity of chlorpromazine alone and combined with N-meglumine antimonate. Ann Trop Med Parasitol 80: 509-517.
131. Chan C, Yin H, Garforth J, McKie JH, Jaouhari R, Speers P et al. 1998. Phenothiazines inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. J Med Chem 41: 148-156.
132. Khan MO, Austin SE, Chan C, Yin H, Marks D, Vaghjiani SN et al. 2000. Use of an additional hydrophobic binding site, the Z site, in the rational design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines. J Med Chem 43: 3148-3156.
133. Loe DW, Stewart RK, Massey TE, Deeley RG, and Cole SPC. 1997. ATP-dependent transport of Aflatoxin B1, and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol 51: 1034-1041.
134. Shudo N, Mizoguchi T, Kiyosue T, Arita M, Yoshimura A, Seto K et al. 1990. Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium blocking activity than their dihydropyrydine counterparts. Cancer Res 50: 3055-3061.
135. Vanhoefer U, Cao S, Minderman H, Toth K, Scheper RJ, Slovak ML et al. 1996. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res 2: 369-377.
136. Sumizawa T, Chen ZS, Chuman Y, Seto K, Furukawa T, Haraguchi M et al. 1997. Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol 51: 399-405.
137. Chen ZS, Mutoh M, Sumizawa T, Furukawa T, Haraguchi M, Tani A et al. 1997. Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells. Biochem Biophys Res Commun 236: 586-590.
138. Chuman Y, Chen ZS, Seto K, Sumizawa T, Furukawa T, Tani A et al. 1998. Reversal of MRP-mediated vincristine resistance in KB cells by buthione sulfoximine in combination with PAK-104P. Cancer Lett 129: 69-76.
139. Kitasono M, Okumura H, Ikeda R, Sumizawa T, Furukawa T, Nagayama S et al. 2001. Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer 91: 126-131.
140. Wernsdorfer WH. 1991. The development and spread of drug-resistant malaria. Parasitol Today 7: 297-303.
141. Trape JF, Pison G, Preziosi MP, Enel C, Desgrées du Loû A, Delauney V et al. 1998. Impact of chloroquine resistance on malaria mortality. C R Acad Sci 321: 689-697.
142. Young MD and Moore DV. 1961. Chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg 10: 317-320.
143. Harinasuta T, Suntharasamai P, and Vivaran C. 1965. Chloroquine-resistant falciparum malaria in Thailand. Lancet 2: 657-660.
144. Cowman AF and Foote S. 1990. Chemotherapy and drug resistance in malaria. Int J Parasitol 20: 503-513.
145. Barnes AJ, Ong EL, Dunbar EM, Mandal BK, and Wilkins EGL. 1991. Failure of chloroquine and proguanil prophylaxis in travellers to Kenya. Lancet 338: 1338-1339.
146. Ringwald P, Bartczak S, Le Bras J, Bricaire F, Matheron S, Bauchet J et al. 1990. Failure of anti-malarial prophylaxis with mefloquine in Africa. Trans R Soc Trop Med Hyg 84: 348-349.
147. Gari-Toussaint M, Pradines B, Mondain V, Keundjian A, Dellamonica P, and Le Fichoux Y. 2002. Sénégal et paludisme. Echec prophylactique vrai de la méflo-quine. Presse Med 31: 1136.
148. Basco LK, Le Bras J, Gillotin C, Ringwald P, Rabenj arson E, Gimenez F et al. 1991. Type RI resistance to halofantrine in West Africa. Trop Med Parasitol 42: 413-414.
149. Molinier S, Imbert P, Verrot D, Morillon M, Parzy D, andTouze JE. 1994. Paludisme à Plasmodiumfalciparum: Résistance de type RI à la quinine en Afrique de l'Est. Presse Med 23: 1484.
150. Wellems TE and Plowe CV. 2001. Chloroquine-resistant malaria. J Infect Dis 184: 770-776.
151. Roepe PD. 2000. What is the precise role of human MDR 1 protein in chemotherapeutic drug resistance. Curr Pharm Design 6: 241-260.
152. Krogstad DJ, Gluzman IY, Kyle DE, Oduola AMJ, Martin SK, Milhous WK, and Schlesinger PH. 1987. Efflux of chloroquine from Plasmodium falciparum: Mechanism of chloroquine resistance. Science 238: 1283-1285.
153. Hunt P, Cravo PVL, Donleavy P, Carlton JMR, and Walliker D. 2004. Chloroquine resistance in Plasmodium chabaudi: Are chloroquine-resistance transporter (crt) and multidrug resistance (mdr1) orthologues involved? Mol Biochem Parasitol 133: 27-35.
154. Cowman AF, Karze S, Galatis D, and Culvenor JG. 1991. A P-glycoprotein homo-logue of Plasmodium falciparum is localized on the digestive vacuole. J Cell Biol 113: 1033-1042.
155. Foote SJ, Thompson JK, Cowman AF, and Kemp DJ. 1989. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P falciparum. Cell 57: 921-930.
156. Wilson CM, Serrano AE, Wasley A, Bogenschutz MP, Shankar AH, and Wirth DF. 1989. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science 244: 1184-1186.
157. Zalis MG, Wilson CM, Zhang Y, and Wirth DF. 1993. Characterization of the pfmdr2 gene for Plasmodium falciparum. Mol Biochem Parasitol 62: 83-92.
158. Rubio JP and Cowman AF. 1994. Plasmodiumfalciparum: The pfmdr2 protein is not overexpressed in chloroquine-resistant isolates of the malaria parasite. Exp Parasitol 79: 137-147.
159. Bozdech Z, Delling U, Volkman SK, Cowman AF, and Schurr E. 1996. Cloning and sequence analysis of a novel member of the ATP-binding cassette (ABC) protein gene family drom Plasmodium falciparum. Mol Biochem Parasitol 81: 41-51.
160. Bozdech Z, Van Wye J, Haldar K, and Schurr E. 1998. The human malaria parasite Plasmodium falciparum exports the ATP-binding cassette protein PFGCN20 to membrane structures in the host red blood cell. Mol Biochem Parasitol 97: 81-95.
161. Klokousas A, Tiffert T, van Schalkwyk D, Wu CP, van Veen HW, Barrand MA et al. 2004. Plasmodium falciparum expresses a multidrug resistance-associated protein. Biochem Biophys Res Commun 321: 197-201.
162. Karcz SR, Galatis D, and Cowman AF. 1993. Nucleotide binding properties of a P-glycoprotein homologue from Plasmodium falciparum. Mol Biochem Parasitol 58: 269-276.
163. Van Es HHG, Karcz S, Chu F, Cowman AF, Vidal S, Gros P, and Schurr E. 1994. Expression of the plasmodial pfmdr1 gene in mammalian cells is associated with increased susceptibility to chloroquine. Mol Cell Biol 14: 2419-2428.
164. Wilson CM, Volkman SK, Thaithong S, Martin RK, Kyle DE, Milhous WK et al. 1993. Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol Biochem Parasitol 57: 151-160.
165. Barnes DA, Foote SJ, Galatis D, Kemp DJ, and Cowman AF. 1992. Selection for high-l evel chloroquine resistance results in deamplification of the pfmdr1 gene and increased sensitivity to mefloquine in Plasmodium falciparum. EMBO J 11: 3067-3075.
166. Basco LK and Ringwald P. 1998. Molecular epidemiology of malaria in Yaoundé, Cameroon. III. Analysis of chloroquine resistance and point mutations in the multidrug resistance 1 (pfmdr1) gene of Plasmodium falciparum. Am J Trop Med Hyg 59: 577-581.
167. Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GAT et al. 1997. Evidence for selection for the tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitology 114: 205-211.
168. Flüeck TPF, Jelinek T, Kilian AHD, Adagu IS, Kabagambe G, von Sonnenburg F et al. 2000. Correlation of in vivo-resistance to chloroquine and allelic polymorphisms in Plasmodium falciparum isolates from Uganda. Trop Med Int Health 5: 174-178.
169. Haruki K, Bray PG, Ward SA, Hommel M, and Ritchie GY. 1994. Chloroquine resistance of Plasmodium falciparum: Further evidence for a lack of association with mutations of the pfmdr1 gene. Trans R Soc Trop Med Hyg 88: 694.
170. Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ et al. 1990. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 345: 255-258.
171. Adagu IS, Dias F, Pinheiro L, Rombo L, do Rosario V, and Warhurst DC. 1996. Guinea Bissau: Association of chloroquine resistance of Plasmodium falciparum with the Tyr86 allele of the multiple drug-resistance gene pfmdr1. Trans R Soc Trop Med Hyg 90: 90-91.
172. Basco LK, Le Bras J, Rhoades Z, and Wilson CM. 1995. Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Mol Biochem Parasitol 74: 157-166.
173. Gomez-Saladin E, Fryauff DJ, Taylor WRJ, Laksana BS, Susanti AI, Subianto B et al. 1999. Plasmodium falciparum mdr1 mutations and in vivo chloroquine resistance in Indonesia. Am J Trop Med Hyg 61: 240-244.
174. Nagesha HS, Din-Syafruddin, Casey GJ, Susanti AI, Fryauff DJ, Reeder JC et al. 2001. Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia. Trans R Soc Trop Med Hyg 95: 43-49.
175. Grobusch MP, Adagu IS, Kremsner PG, and Warhurst DC. 1998. Plasmodium falciparum. In vitro chloroquine susceptibility and allele-specific PCR detection of Pfmdr1 Asn86Tyr polymorphism in Lambarene, Gabon. Parasitology 116: 211-217.
176. Bhattacharya PR, Biswas S, and Kabilan L. 1997. Alleles of the Plasmodiumfal-ciparum Pfmdr1 gene appear not to be associated with chloroquine resistance in India. Trans R Soc Trop Med Hyg 91: 454-455.
177. Awad el Kariem FM, Miles MA, and Warhurst DC. 1992. Chloroquine-resistant Plasmodium falciparum isolates from the Sudan lack two mutations in the pfmdr1 gene thought to be associated with chloroquine resistance. Trans R Soc Trop Med Hyg 86: 587-589.
178. Basco LK, de Pecoulas PE, Le Bras J, and Wilson CM. 1996. Plasmodiumfalci-parum: Molecular characterization of multidrug-resistant Cambodian isolates. Exp Parasitol 82: 97-103.
179. von Seidlein L, Duraisingh MT, Drakeley CJ, Bailey R, Greenwood BM, and Pinder M. 1997. Polymorphism of the Pfmdr1 gene and chloroquine resistance in Plasmodium falciparum in The Gambia. Trans R Soc Trop Med Hyg 91: 450-453.
180. Povoa MM, Adagu IS, Oliveira SG, Machado RLD, Miles MA, and Warhurst DC. 1998. Pfmdr1 Asn1042Asp and Asp1246Tyr polymorphisms, thought to be associated with chloroquine resistance, are present in chloroquine-resistant and-sensitive Brazilian field isolates of Plasmodium falciparum. Exp Parasitol 88: 64-68.
181. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C et al. 2003. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 47: 2418-2423.
182. van Es HH, Renkema H, Aerts H, and Schurr E. 1994. Enhanced lysosomal acidification leads to increased chloroquine accumulation in CHO cells expressing the pfmdr1 gene. Mol Biochem Parasitol 6: 209-219.
183. Yayon A, Cabantchik ZI, and Ginsburg H. 1985. Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc Natl Acad Sci USA 82: 2784-2788.
184. Bray PG, Howells RE, and Ward SA. 1992. Vacuolar acidification and chloroquine sensitivity in Plasmodium falciparum. Biochem Pharmacol 43: 1219-1227.
185. Dzekunov SM, Ursos LMB, and Roepe PD. 2000. Digestive vacuolar pH of intact intraerythrocytic P. falciparum either sensitive or resistant to chloroquine. Mol Biochem Parasitol 110: 107-124.
186. Saliba KJ, Folb PI, and Smith PJ. 1998. Role for the Plasmodiumfalciparum digestive vacuole in chloroquine resistance. Biochem Parasitol 56: 313-320.
187. Fitch CD. 1986. Antimalarial schizonticides: Ferriprotoporphyrin IX interaction hypothesis. Parasitol Today 2: 330-331.
188. Krogstad DJ, Schlesinger PH, and Gluzman IY. 1985. Antimalarials increase vesicle pH in Plasmodium falciparum. J Cell Biol 101: 2302-2309.
189. Bray PG, Boulter MK, Ritchie GY, Howells RE, and Ward SA. 1994. Relationship of global chloroquine transport and reversal of resistance in Plasmodium falciparum. Mol Biochem Parasitol 63: 87-94.
190. Ursos LMB, Dzekunov SM, and Roepe PD. 2000. The effects of chloroquine and verapamil on digestive vacuolar pH of P. falciparum either sensitive or resistant to chloroquine. Mol Biochem Parasitol 110: 125-134.
191. Bray PG, Jenneh O, Raynes KJ, Mungthin M, Ginsburg H, and Ward SA. 1999. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J Cell Biol 145: 363-376.
192. Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, and Ridley RG. 1998. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol 55: 727-736.
193. Pagola S, Stephens PW, Bohle DS, Kosar AD, and Madsen SK. 2000. The structure of malaria pigment beta-haematin. Nature 404: 307-310.
194. Hempelmann E and Egan TJ. 2002. Pigment biocrystallization in Plasmodium falciparum Trends Parasitol 18: 11.
195. Ursos LMB, DuBay KF, and Roepe PD. 2001. Antimalarial drugs influence the pH dependent solubility of heme via apparent nucleation phenomena. Mol Biochem Parasitol 112: 11-17.
196. Ruetz S, Delling U, Brault, M, Schurr E, and Gros P. 1996. The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells. Proc Natl Acad Sci USA 93: 9942-9947.
197. Volkman SK, Wilson CM, and Wirth DF. 1993. Stage-specific transcripts of the Plasmodium falciparum pfmdr1 gene. Mol Biochem Parasitol 57: 203-211.
198. Cowman AF, Galatis D, and Thompson JK. 1994. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA 91: 1143-1147.
199. Peel SA, Bright P, Yount B, Handy J, and Baric RS. 1994. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. Am J Trop Med Hyg 51: 648-658.
200. Zalis MG, Pang L, Silveira MS, Milhous WK, and Wirth DF. 1998. Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: Evidence for quinine resistance. Am J Trop Med Hyg 58: 630-637.
201. Lim AS, Galatis D, and Cowman AF. 1996. Plasmodiumfalciparum: Amplification and overexpression of pfmdr1 is not necessary for inreased mefloquine resistance. Exp Parasitol 86: 295-303.
202. Ritchie GY, Mungthin M, Green JE, Bray PG, Hawley SR, and Ward SA. 1996. In vitro selection of halofantrine resistance in Plasmodium falciparum is not associated with increased expression of Pgh1. Mol Biochem Parasitol 83: 35-46.
203. Price RC, Uhlemann AC, Brockman A, McReady R, Asley E, Phaipun L et al. 2004. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364: 438-447.
204. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ et al. 1999. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother 43: 2943-2949.
205. Reed MB, Saliba KJ, Caruana SR, Kirk K, and Cowman AF. 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403: 906-909.
206. Basco LK and Ringwald P. 2002. Molecular epidemiology of malaria in Cameroon. X. Evaluation of pfmdr1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives. Am J Trop Med Hyg 66: 667-671.
207. Mawili-Mboumba DP, Kun JFJ, Lell B, Kremsner PG, and Ntoumi F. 2002. Pfmdr1 alleles and response to ultralow-dose mefloquine treatment in Gabonese patients. Antimicrob Agents Chemother 46: 166-170.
208. Pillai DR, Hijar G, Montoya I, Marquino W, Ruebush TK, Wrongsrichanalai C et al. 2003. Lack of prediction of mefloquine and mefloquine-artesunate treatment outcome by mutations in the Plasmodium falciparum multidrug resistance 1 (pfmdr1) gene for P falciparum malaria in Peru. Am J Trop Med Hyg 68: 107-110.
209. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, and Warhurst DC. 2000. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol 108: 13-23.
210. Duraisingh MT, Roper C, Walliker D, and Warhurst DC. 2000. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol 36: 955-961.
211. Ngo T, Duraisingh M, Reed M, Hipgrave D, Biggs B, and Cowman AF. 2003. Analysis of pfcrt, pfmdr1, dhfr, and dhps mutations and drug sensitivities in Plasmodium falciparum isolates from patients in Vietnam before and after treatment with artemisinin. Am J Trop Med Hyg 68: 350-356.
212. Carlton J, Mackinnon M, and Walliker D. 1998. A chloroquine resistance locus in the rodent malaria parasite Plasmodium chabaudi. Mol Biochem Parasitol 93: 57-72.
213. Cravo PVL, Carlton JMR, Hunt P, Bisoni L, Padua RA, and Walliker D. 2003. Genetics of mefloquine resistance in the rodent malaria parasite Plasmodium chabaudi. Antimicrob Agents Chemother 47: 709-718.
214. Ferrer-Rodriguez I, Perez-Rosado J, Gervais GW, Peters W, Robinson BL, and Serrano AE. 2004. Plasmodium yoelii: Identification and partial characterization of an MDR1 gene in an artemisini-resistant line. J Parasitol 90: 152-160.
215. Gervais GW, Trujillo K, Robinson BL, Peters W, and Serrano AE. 1999. Plasmodium berghei: Identification of an mdr-. ike gene associated with drug resistance. Exp Parasitol 91: 86-92.
216. Ekong RM, Robson KJ, Baker DA, and Warhurst DC. 1993. Transcripts of the multidrug resistance genes in chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Parasitology 106: 107-115.
217. Bozdech Z and Schurr E. 1999. Protein transport in the host cell cytoplasm and ATP-binding cassette proteins in Plasmodium falciparum-infected erythrocytes. Novartis Found Symp 226: 231-241.
218. Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T et al. 2003. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol 49: 977-989.
219. Ursing J, Zakeri S, Gil JP, and Bjorkman A. 2006. Quinoline resistance associated polymorphisms in the pfcrt, pfmdr1 and pfmrp genes of Plasmodium falciparum in Iran. Acta Trop 97: 352-356.
220. Bray PG, Hawley SR, Mungthin M, and Ward SA. 1996. Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum. Mol Pharmacol 50: 1559-1566.
221. Kyle DE, Oduola AM, Martin SK, and Milhous WK. 1990. Plasmodium falciparum: Modulation by calcium antagonists of resistance to chloroquine, deseth-ylchloroquine, quinine, and quinidine in vitro. Trans R Soc Trop Med Hyg 84: 474-478.
222. Menezes CM, Kirchgatter K, Di Santi M, Savalli C, Monteiro FG, Paula GA et al. 2003. In vitro evaluation of verapamil and other modulating agents in Brazilian chloroquine-resistant Plasmodiumfalciparum isolates. Rev Soc Bras Med Trop 36: 5-9.
223. Kyle E, Milhous WK, and Rossan RN. 1993. Reversal of Plasmodiumfalciparum resistance to chloroquine in Panamanian Aotus monkeys. Am J Trop Med Hyg 48: 126-133.
224. Millet J, Torrentino-Madamet M, Alibert S, Rogier C, Santelli-Rouvier C, Mosnier J et al. 2004. Dihydroethanoanthracene derivatives as m vitro malarial chloroquine resistance reversal agents. Antimicrob Agents Chemother 48: 2753-2756.
225. Bayoumi RA, Creasey AM, Babiker HA, Carlton JM, Sultan AA, Satti G et al. 1993. Drug response and genetic characterization of Plasmodium falciparum clones recently isolated from a Sudanese village. Trans R Soc Trop Med Hyg 87: 454-458.
226. Bayoumi RAL, Babiker HA, and Arnot DE. 1994. Uptake and efflux of chloro-quine by chloroquine-resistant Plasmodium falciparum clones recently isolated in Africa. Acta Trop 58: 141-149.
227. Bray PG, Howells RE, Pitchie GY, and Ward SA. 1992. Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. A correlation of chloroquine sensitivity with energy-dependent drug accumulation. Biochem Pharmacol 44: 1317-1324.
228. Ginsburg H and Krugliak M. 1992. Quinoline-containing antimalarials-Mode of action, drug resistance and its reversal. An update with unresolved puzzles. Biochem Pharmacol 43: 63-70.
229. Verdier F, Le Bras J, Clavier F, Hatin I, and Blayo M. 1985. Chloroquine uptake by Plasmodium falciparum-mfected human erythrocytes during m vitro culture and its relationship to chloroquine resistance. Antimicrob Agents Chemother 27: 561-564.
230. Ferrari V and Cutler DJ. 1991. Simulation of kinetic data on the influx and efflux of chloroquine by erythrocytes infected with Plasmodium falciparum. Evidence for a drug-importer in chloroquine-sensitive strains. Biochem Pharmacol 42: S167-S179.
231. Taylor D, Walden JC, Robins AH, and Smith PJ. 2000. Role of the neurotransmitter reuptake-blocking activity of antidepressants in reversing chloroquine resistance in vitro in Plasmodium falciparum. Antimicrob Agents Chemother 44: 2689-2692.
232. Martiney JA, Cerami A, and Slater AFG. 1995. Verapamil reversal of chloroquine resistance in the malaria parasite Plasmodium falciparum is specific for resistant parasites and independent of the weak base effect. J Biol Chem 270: 22393-22398.
233. Oduola AM, Sowunmi A, Milhous WK, Brewer TG, Kyle E, Gerena L et al. 1998. In vitro and in vivo reversal of chloroquine resistance in Plasmodium falciparum with promethazine. Am J Trop Med Hyg 58: 625-629.
234. Pradines B, Alibert-Franco S, Houdoin C, Mosnier J, Santelli-Rouvier C, Papa V et al. 2002. In vitro reversal of chloroquine resistance in Plasmodium falciparum with dihydroethanoanthracene derivatives. Am J Trop Med Hyg 66: 661-666.
235. Gerena L, Bass GT, Kyle DE, Oduola AM, Milhous WK, and Martin RK. 1992. Fluoxetine hydrochloride enhances in vitro susceptibility to chloroquine in resistant Plasmodium falciparum. Antimicrob Agents Chemother 36: 2761-2765.
236. Pradines B, Alibert S, Houdoin C, Santelli-Rouvier C, Mosnier J, Fusai T et al. 2002. In vitro increase in chloroquine accumulation induced by dihydroethano-and ethenoanthracene derivatives in Plasmodium falciparum-parasitized erythrocytes. Antimicrob Agents Chemother 46: 2061-2068.
237. Walter RD, Seth M, and Bhaduri AP. 1993. Reversal of chloroquine resistance in Plasmodium falciparum by CDR 87/209 and analogues. Trop Med Parasitol 44: 5-8.
238. Haruki K, Bray G, Ono M, and Ward SA. 2000. Potent enhancement of the sensitivity of Plasmodium falciparum to chloroquine by the bisbenzylisoquinoline alkaloid cepharanthin. Antimicrob Agents Chemother 44: 2706-2708.
239. Jacobs GH, Oduola AMJ, Kyle DE, Milhous WK, Martin SK, and Aikawa M. 1988. Ultrastructural study of the effects of chloroquine and verapamil on Plasmodium falciparum. Am J Trop Med Hyg 39: 15-20.
240. Tanabe K, Kato M, Izumo A, Hagiwara A, and Doi S. 1990. Plasmodium chabaudi: In vivo effects of Ca2+ antagonists on chloroquine. resistant and chloroquine. sensitive parasites. Exp Parasitol 70: 419-426.
241. Deloron P, Basco LK, Dubois B, Gaudin C, Clavier F, Le Bras J et al. 1991. In vitro and in vivo potentiation of chloroquine against malaria parasites by an enantiomer of amlodipine. Antimicrob Agents Chemother 35: 1338-1342.
242. Platel DF, Mangou F, and Tribouley-Duret J. 1998. High-level chloroquine resistance of Plasmodium berghei is associated with multiple drug resistance and loss of reversal by calcium antagonists. Int J Parasitol 28: 641-651.
243. Johnson DJ, Fidock DA, Mungthin M, Lakshmanan V, bir Singh Sidhu A, Bray PG et al. 2004. Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol Cell 15: 867-877.
244. Sidhu ABS, Verdier-Pinard D, and Fidock DA. 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298: 210-213.
245. Kalkanidis M, Klonis N, Tilley L, and Deady LW. 2002. Novel phenothiazine anti-malarials: Synthesis, antimalarial activity, and inhibition of the formation of beta-haematin. Biochem Pharmacol 63: 833-842.
246. Menezes CMS, Kirchgatter K, di Santi SM, Savall C, Monteiro FG, Paula GA et al. 2002. In vitro chloroquine resistance modulation study on fresh isolates of Brazilian Plasmodium falciparum: Intrinsic antimalarial activity of phenothiazine drugs. Mem Inst Oswaldo Cruz 97: 1033-1039.
247. Guan J, Kyle DE, Gerena L, Zhang Q, Milhous WK, and Lin AJ. 2002. Design, synthesis, and evaluation of new chemosensitizers in multi-drug-resistant Plasmodium falciparum. J Med Chem 45: 2741-2748.
248. Amaral L, Kristiansen JE, and Lorian V. 1992. Synergic effect of chlorpromazine on the activity of some antibiotics. J Antimicrob Chemother 30: 556-558.
249. Viveiros M and Amaral L. 2001. Enhancement of antibiotic activity against polydrug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 17: 225-228.
250. Gracio MA, dos Santos Gracio AJ, Viveiros M, and Amaral L. 2003. Since pheno-thiazines alter antibiotic susceptibility of microorganisms by inhibiting efflux pumps, are these agents useful for evaluating similar pumps in phenothiazine-sensitive parasites? Int JAntimicrob Agents 22: 347-351.
251. Kolaczlowski M, Michalak K, and Motohashi N. 2003. Phenothiazines as potent modulators of yeast multidrug resistance. Int J Antimicrob Agents 22: 279-283.
252. Mehlotra RK, Fusioka H, Roepe PD, Janneh O, Ursos LMB, Jacobs-Lorena V et al. 2001. Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc Natl Acad Sci USA 98: 12689-12694.
253. Zamora JM, Pearce HL, and Beck WT. 1988. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33: 454-462.
254. Miki A, Tanabe K, Nakayama T, Kiryon C, and Ohsawa K. 1992. Plasmodium chabaudi: Association of reversal of chloroquine resistance with increased accumulation of chloroquine in resistant parasites. Exp Parasitol 74: 134-142.
255. Bitonti AJ, Sjoerdsma A, McCann PP, Kyle DE, Oduola AMJ, Rossan RN et al. 1988. Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science 242: 1301-1303.
256. Bitonti AJ and McCann PP. 1989. Desipramine and cyproheptadine for reversal of chloroquine resistance in Plasmodium falciparum. Lancet 2: 1282-1283.
257. Salama A and Facer CA. 1990. Desipramine reversal of chloroquine resistance in wild isolates of Plasmodium falciparum. Lancet 335: 164-165.
258. Basco LK and Le Bras J. 1990. Reversal of chloroquine resistance with desipra-mine in isolates of Plasmodium falciparum from Central and West Africa. Trans R Soc Trop Med Hyg 84: 479-481.
259. Carosi G, Caligaris S, Fadat G, Castelli F, Matteelli A, Kouka-Bemba D et al. 1991. Reversal of chloroquine resistance of "wild" isolates of Plasmodium falciparum by desipramine. Trans R Soc Trop Med Hyg 85: 723-724.
260. Boulter MK, Bray PG, Howells RE, and Ward SA. 1993. The potential of desip-ramine to reverse chloroquine resistance of Plasmodium falciparum is reduced by its binding to plasma protein. Trans R Soc Trop Med Hyg 87: 303.
261. Menezes CMS, Kirchgatter K, di Santi SM, Savalli C, Monteiro FG, Paula GA et al. 1997. Antimalarial effect in vitro and lack of modulating effect of desipra-mine and imipramine. Trans R Soc Trop Med Hyg 91: 697-700.
262. Warsame M, Wernsdorfer WH, and Björkman A. 1992. Lack of effect of desipra-mine on the response to chloroquine of patients with chloroquine-resistant falciparum malaria. Trans R Soc Trop Med Hyg 86: 235-236.
263. Evans SG, Butkow N, Stilwell C, Berk M, Kirchmann N, and Havlik I. 1998. Citalopram enhances the activity of chloroquine in resistant Plasmodium in vitro and in vivo. J Pharmacol Exp Ther 286: 172-174.
264. Bhattacharjee AK, Kyle DE, Vennerstrom JL, and Milhous WK. 2002. A 3D QSAR pharmacophore model and quantum chemical structure-Activity analysis of chloroquine (CQ). resistance reversal. J Chem Inf Comput Sci 42: 1212-1220.
265. Bhattacharjee AK, Kyle DE, and Vennerstrom JL. 2001. Structural analysis of chloroquine resistance reversal by imipramine analogs. Antimicrob Agents Chemother 45: 2655-2657.
266. Basco LK and Le Bras J. 1990. Desipramine or cyproheptadine for reversing chloroquine resistance? Lancet 335: 422.
267. Basco LK, Ringwald P, and Le Bras J. 1991. Chloroquine-potentiating action of antihistaminics in Plasmodium falciparum in vitro. Ann Trop Med Parasitol 85: 223-228.
268. Peters W, Ekong R, Robinson BL, and Warhurst DC. 1990. The chemotherapy of rodent malaria. XLV. Reversal of chloroquine resistance in rodent and human Plasmodium by antihistaminic agents. Ann Trop Med Parasitol 84: 541-551.
269. Singh N and Puri SK. 2000. Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis. Acta Trop 77: 185-193.
270. Oduola OO, Happi TC, Gbotosho GO, Ogundahunsi OA, Falade CO, Akinboye DO et al. 2004. Plasmodium berghei: Efficacy and safety of combinations of chlo-roquine and promethazine in chloroquine resistant infections in gravid mice. Afr J Med Sci 33: 77-81.
271. Oduola AMJ, Sowunmi A, Milhous WK, Brewer TG, Kyle DE, Gerena L et al. 1998. In vitro and in vivo reversal of chloroquine resistance in Plasmodiumfalci-parum with promethazine. Am J Trop Med Hyg 58: 625-629.
272. Sowunmi A, Oduola AMJ, Ogundahunsi OAT, Falade CO, Gbotosho GO, and Salako LA. 1997. Enhanced efficacy of chloroquine-chlorpheniramine combination in acute uncomplicated falciparum malaria in children. Trans R Soc Trop Med Hyg 91: 63-67.
273. Sowunmi A, Oduola AMJ, Ogundahunsi OAT, and Salako LA. 1998. Comparative efficacy of chloroquine plus chlorpheniramine and pyrimethamine/sulfadoxine in acute uncomplicated falciparum malaria in Nigerian children. Trans R Soc Trop Med Hyg 92: 77-81.
274. Sowunmi A, Fehintola FA, Ogundahunsi OAT, and Oduola AMJ. 1998. Comparative efficacy of chloroquine plus chlorpheniramine and halofantrine in acute uncomplicated falciparum malaria in Nigerian children. Trans R Soc Trop Med Hyg 92: 441-445.
275. Okonkwo CA, Coker HAB, Agomo PU, Ogunbanwo JA, Mafe AG, Agomo CO et al. 1999. Effect of chlorpheniramine on the pharmacokinetics of and response to chloroquine of Nigerian children with falciparum malaria. Trans R Soc Trop Med Hyg 93: 306-311.
276. Singh N and Puri SK. 2000. Modulation of halofantrine resistance after coadministration of halofantrine with diverse pharmacological agents in a rodent malaria model. Life Sci 67: 1345-1354.
277. Crandall I, Charuk J, and Kain KC. 2000. Nonylphenolethoxylates as malarial chloroquine resistance reversal agents. Antimicrob Agents Chemother 44: 2431-2434.
278. Ciach M, Zong K, Kain KC, and Crandall I. 2003. Reversal of mefloquine and quinine resistance in Plasmodium falciparum with NP30. Antimicrob Agents Chemother 47: 2393-2396.
279. Loe W and Sharom FJ. 1993. Interaction of multidrug-resistant Chinese hamster ovary cells with amphiphiles. Br J Cancer 68: 342-351.
280. Shalmiev G and Ginsburg H. 1993. The susceptibility of the malarial parasite Plasmodium falciparum to quinoline-containing drugs is correlated to the lipid composition of the infected erythrocyte membranes. Biochem Pharmacol 46: 365-374.
281. Sidhu AB, Valderramos SG, and Fidock DA. 2005. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol 57: 913-926.
282. Peel SA, Bright P, Yount B, Handy J, and Baric RS. 1994. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. Am J Trop Med Hyg 51: 648-658.
283. Nelson AL, Purfield A, McDaniel P, Uthaimongkol N, Buathong N, Sriwichai S et al. 2005. pfmdr1 genotyping and in vivo mefloquine resistance on the Thai-Myanmar border. Am J Trop Med Hyg 72: 586-592.
284. Duraisingh MT, Roper C, Walliker D, and Warhurst DC. 2000. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol 36: 955-961.
285. Wu CP, Klokouzas A, Hladky SB, Ambudkar SV, and Barrand MA. 2005. Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes. Biochem Pharmacol 70: 500-510.
286. Oduola AM, Omitowoju GO, Gerena L, Kyle DE, Milhous WK, Sowunmi A et al. 1993. Reversal of mefloquine resistance with penfluridol in isolates of Plasmodium falciparum from south-west Nigeria. Trans R Soc Trop Med Hyg 87: 81-83.
287. Mungthin M, Bray PG, and Ward SA. 1999. Phenotypic and genotypic characteristics of recently adapted isolates of Plasmodium falciparum from Thailand. Am J Trop Med Hyg 60: 469-474.
288. Peters W and Robinson BL. 1991. The chemotherapy of rodent malaria. XLVI. Reversal of mefloquine resistance in rodent Plasmodium. Ann Trop Med Parasitol 85: 5-10.